Onconova Therapeutics, Inc. (ONTX)
(Delayed Data from NSDQ)
$4.07 USD
0.00 (0.00%)
Updated May 3, 2019 04:00 PM ET
After-Market: $4.16 (%) 5:22 PM ET
NA Value NA Growth NA Momentum NA VGM
View All Zacks #1 Ranked Stocks
Brokerage Reports
0 items in cart
Traws Pharma, Inc. [ONTX]
Reports for Purchase
Showing records 1 - 20 ( 74 total )
Company: Traws Pharma, Inc.
Industry: Medical - Drugs
Narazaciclib Continues to Build a Differentiated Preclinical Profile; Clinical Updates in 1H24
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Price: 12.50
Company: Traws Pharma, Inc.
Industry: Medical - Drugs
3Q23 Results; Significant Narazaciclib Milestones on the Horizon
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Price: 12.50
Company: Traws Pharma, Inc.
Industry: Medical - Drugs
Preclinical Data Update Expands Potential For Narazaciclib in MCL
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Price: 12.50
Company: Traws Pharma, Inc.
Industry: Medical - Drugs
Rigosertib Continues to Make Promising Moves in RDEB
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Price: 12.50
Company: Traws Pharma, Inc.
Industry: Medical - Drugs
2Q23 Results; Narazaciclib Approaching Important Milestones; Solid Tumor and LGEEC Data in 4Q23
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Price: 12.50
Company: Traws Pharma, Inc.
Industry: Medical - Drugs
Narazaciclib''s Differentiated Profile Continues to Carve an Exciting New Path
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Price: 12.50
Company: Traws Pharma, Inc.
Industry: Medical - Drugs
Rigosertib''s Steadfast Journey in RDEB Highlighted at ASCO
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Price: 12.50
Company: Traws Pharma, Inc.
Industry: Medical - Drugs
Rigosertib''s Journey Into Melanoma Begins With First Patient Dosed in Phase 2 Combination Trial
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Price: 12.50
Company: Traws Pharma, Inc.
Industry: Medical - Drugs
1Q23 Results; Focus on Narazaciclib Upcoming Data and Rigosertib Regulatory Visibility
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Price: 12.50
Company: Traws Pharma, Inc.
Industry: Medical - Drugs
Narazaciclib Pushes Forward; First Patient Dosed in Phase 1/2a Combination Trial
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Price: 12.50
Company: Traws Pharma, Inc.
Industry: Medical - Drugs
Time To Look At Narazaciclib and Intriguing Rigosertib RDEB-SCC Opportunities; Upgrade to Buy; $11 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Price: 12.50
Company: Traws Pharma, Inc.
Industry: Medical - Drugs
New Collaboration Supports Rigosertib?s Potential Expansion Into New Solid Tumor Indications
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Price: 12.50
Company: Traws Pharma, Inc.
Industry: Medical - Drugs
2022 Results; Narazaciclib and Rigosertib Closer to New Datasets and Prepping for Additional Trials
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Price: 12.50
Company: Traws Pharma, Inc.
Industry: Medical - Drugs
Rigosertib Could Deliver Meaningful Impact to Dire Consequence in RDEB patients.
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Price: 5.00
Company: Traws Pharma, Inc.
Industry: Medical - Drugs
3Q22 Results; Narazaciclib Ready to Launch a New Phase 1/2 Trial in EC in 1Q23; Rigosertib Progressing as Planned
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Price: 12.50
Company: Traws Pharma, Inc.
Industry: Medical - Drugs
2Q22 Results; Narazaciclib and Rigosertib Enrolling Steadily in Multiple Clinical Trials
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Price: 12.50
Company: Traws Pharma, Inc.
Industry: Medical - Drugs
1Q22 Results; Clinical Pipeline Matures in Multiple Solid Tumor Indications; Program Updates Expected in 2H22
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Price: 12.50
Company: Traws Pharma, Inc.
Industry: Medical - Drugs
2021 Results; Narazaciclib Draws Closer to Phase 2 Trial; Rigosertib Shows Promise in RDEB-Associated SCC and NSCLC
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Price: 12.50
Company: Traws Pharma, Inc.
Industry: Medical - Drugs
Rigosertib Shows Early Activiy in RDEB-Associated SCC
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Price: 12.50
Company: Traws Pharma, Inc.
Industry: Medical - Drugs
3Q21 Results; Steady as She Goes; Multiple Assets Continue to Advance Through Pipeline
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Price: 12.50